Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

Umbelina  Caixas; Sofia A Pereira; Emília C Monteiro; Ana Luisa  Papoila

doi:10.1111/j.1365-2125.2008.03238.x

Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

Umbelina Caixas, Sofia A Pereira, Emília C Monteiro, Ana Luisa Papoila

NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

AIMS Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.

Original language	English
Pages (from-to)	551-555
Number of pages	5
Journal	British Journal of Clinical Pharmacology
Volume	66
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2125.2008.03238.x
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2125.2008.03238.x

Cite this

@article{989e9e94b6bc4b0a948cd187d0aea440,

title = "Efavirenz concentrations in HIV-infected patients with and without viral hepatitis",

abstract = "AIMS Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.",

keywords = "ADVERSE EVENTS, ANTIRETROVIRAL THERAPY, viral hepatitis co-infection, PLASMA-CONCENTRATIONS, HUMAN-IMMUNODEFICIENCY-VIRUS, REVERSE-TRANSCRIPTASE INHIBITORS, COINFECTION, efavirenz concentrations, NEVIRAPINE, LIVER TOXICITY, HIV-1-INFECTED PATIENTS, liver function, INTRAINDIVIDUAL VARIABILITY",

author = "Umbelina Caixas and Pereira, {Sofia A} and Monteiro, {Em{\'i}lia C} and Papoila, {Ana Luisa}",

year = "2008",

doi = "10.1111/j.1365-2125.2008.03238.x",

language = "English",

volume = "66",

pages = "551--555",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

AU - Caixas, Umbelina

AU - Pereira, Sofia A

AU - Monteiro, Emília C

AU - Papoila, Ana Luisa

PY - 2008

Y1 - 2008

N2 - AIMS Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.

AB - AIMS Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.

KW - ADVERSE EVENTS

KW - ANTIRETROVIRAL THERAPY

KW - viral hepatitis co-infection

KW - PLASMA-CONCENTRATIONS

KW - HUMAN-IMMUNODEFICIENCY-VIRUS

KW - REVERSE-TRANSCRIPTASE INHIBITORS

KW - COINFECTION

KW - efavirenz concentrations

KW - NEVIRAPINE

KW - LIVER TOXICITY

KW - HIV-1-INFECTED PATIENTS

KW - liver function

KW - INTRAINDIVIDUAL VARIABILITY

U2 - 10.1111/j.1365-2125.2008.03238.x

DO - 10.1111/j.1365-2125.2008.03238.x

M3 - Article

C2 - 18662298

VL - 66

SP - 551

EP - 555

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 4

ER -

Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this